Drug Profile
Research programme: inhaled muscarinic M3 receptor antagonists - Pfizer
Alternative Names: PF-4522971Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Pfizer
- Class
- Mechanism of Action Muscarinic M3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Chronic obstructive pulmonary disease
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Chronic-obstructive-pulmonary-disease in United Kingdom (Inhalation, Inhalant)
- 22 Sep 2010 Preclinical trials in Chronic obstructive pulmonary disease in United Kingdom (Inhalation)
- 22 Sep 2010 Pharmacodynamics data from an In vitro trial presented at the 20th Annual Congress of the European Respiratory Society (ERS-2010)